Watch the Longevity.Technology interview of Dr. Oki O’Connor on “Cyclarity’s elegant solution to one of the world’s biggest problems – atherosclerosis.”
Dr. O’Connor and Phil Newman discuss:
- The unique Cyclarity platform.
- The nature of cyclodextrins.
- The opportunities in the cyclodextrin market.
- The size of the problem.
We’re thrilled to be working towards reversing the world’s leading killer and thankful to Longevity.Technology for bringing a focus to our novel treatment.
About Cyclarity
Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com
Forward Looking Statements
The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.
Contact:
Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com